This webcast aims to address the unmet needs of Migraine and what impacts patients the most while highlighting on the new CGRP Monoclonal Antibodies’ effectiveness to address the unmet needs that the health care provider face in their clinics.
1- Address the unmet need in prevention of Migraine and understand its impact on patients.
2- Understand the Real-World data on effectiveness, safety and tolerability of CGRPs in respect to the clinical trials.
3- Identify the appropriate patients for CGRP Monoclonal Antibodies.
Consultant Neurologist & Head Section of Neurology Division Prince Mohammad Bin Abdulaziz National Guard Hospital in Madinah
MD, FRCPC, FAAN Consultant Neurologist, Adjunct Part-time Assistant Professor of Neurology, Johns Hopkins Medicine, Saudi Arabia.